Literature DB >> 23629491

Maturing antibody-drug conjugate pipeline hits 30.

Asher Mullard.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23629491     DOI： 10.1038/nrd4009

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  87 in total

1.  Recent advances in the construction of antibody-drug conjugates.

Authors:  Vijay Chudasama; Antoine Maruani; Stephen Caddick
Journal:  Nat Chem       Date:  2016-01-04       Impact factor: 24.427

Review 2.  Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies.

Authors:  Antoine Deslandes
Journal:  MAbs       Date:  2014-04-25       Impact factor: 5.857

3.  Organocatalysts of oxidative protein folding inspired by protein disulfide isomerase.

Authors:  John C Lukesh; Kristen A Andersen; Kelly K Wallin; Ronald T Raines
Journal:  Org Biomol Chem       Date:  2014-11-21       Impact factor: 3.876

Review 4.  Building better monoclonal antibody-based therapeutics.

Authors:  George J Weiner
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 5.  Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.

Authors:  S Sadekar; I Figueroa; M Tabrizi
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

Review 6.  An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.

Authors:  Janice A Lansita; John M Burke; Joshua F Apgar; Barbara Mounho-Zamora
Journal:  Pharm Res       Date:  2015-06-25       Impact factor: 4.200

Review 7.  Antibody Drug Conjugates: Nonclinical Safety Considerations.

Authors:  Mary Jane Masson Hinrichs; Rakesh Dixit
Journal:  AAPS J       Date:  2015-05-30       Impact factor: 4.009

8.  Target-mediated drug disposition model and its approximations for antibody-drug conjugates.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-12-11       Impact factor: 2.745

9.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

10.  Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico.

Authors:  Kelly C Falls; Ricky A Sharma; Yaacov R Lawrence; Richard A Amos; Sunil J Advani; Mansoor M Ahmed; Bhadrasain Vikram; C Norman Coleman; Pataje G Prasanna
Journal:  Radiat Res       Date:  2018-10       Impact factor: 2.841
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.